BPC-157July 23
Studied for gut healing, tissue and tendon repair, and anti-inflammatory effects.
Where we fight
The policies that govern peptide access
AAPM advances patient access and safety through focused advocacy on the decisions that determine how, and whether, Americans can obtain peptide therapies.
01
Advocating for Safe, Legal Access
Advocating to place these peptides in Category 1 so patients can obtain them through licensed U.S. compounding pharmacies, under a valid prescription and physician oversight.
- Advocate for Category 1 classification
- Support licensed compounding access
- Promote physician-supervised use
- Engage with FDA and PCAC
02
Clinician Education and Standards
Training and credentialing clinicians through the PepMed program so peptides are prescribed responsibly, dosed correctly, and monitored over time.
- PepMed certification program
- Responsible prescribing
- CE credit eligibility
- Ongoing monitoring standards
03
Ending the Gray-Market Danger
Replacing unregulated online and international sources with regulated channels held to USP 795 and 797 standards for sterility, potency, and purity.
- USP 795 and 797 standards
- Sterility and potency testing
- Accredited compounding only
- Patient safety frameworks
Flagship Event
Annual Conference — Washington, D.C.
Each September, AAPM convenes clinicians, researchers, and policymakers for scientific programming, peer exchange, and direct policy engagement in the nation's capital.
Take action • Track the hearing
Peptides under FDA review
The FDA Pharmacy Compounding Advisory Committee will review each compound removed from the Category 2 list. Track every peptide, its review day, and where it stands.
TB-500July 23
A Thymosin Beta-4 fragment studied for muscle repair and recovery.
KPVJuly 23
A tripeptide with documented anti-inflammatory and gut-supportive properties.
MOTs-CJuly 23
A mitochondrial-derived peptide studied for metabolic regulation.
DSIPJuly 24
Delta sleep-inducing peptide, studied for sleep and stress response.
SemaxJuly 24
Studied for cognitive support and neuroprotection.
EpitalonJuly 24
Studied for cellular aging and circadian regulation.
Removal from Category 2 is not FDA approval. These compounds remain prescription-only and require individualized physician evaluation through a licensed provider and an accredited compounding pharmacy.
Tell the FDA where you standState of play
How we got here
The 2023 restrictions did not eliminate demand. They eliminated regulation. This is the path back to physician-supervised, regulated access.
- 2023
14 widely used peptides are placed on the Category 2 restricted list, pushing patients toward unregulated sources.
- Feb 2026
HHS signals intent to begin restoring safe, physician-supervised, legally compounded access.
- Apr 15, 2026
Peptides are formally removed from the do-not-compound list, effective within seven calendar days.
- Jul 23-24, 2026
The PCAC advisory committee hearing is held at the FDA White Oak Campus in Silver Spring, Maryland.
Why AAPM
The credibility behind the Academy
Bipartisan leadership
Our founding advisory board includes former governors from both parties, signaling that patient access to safe peptide medicine transcends party lines.
Regulatory expertise
Board members include FDA regulatory attorneys, pharmacy law experts, and former state officials with deep experience in healthcare policy and compliance.
A unified field
Each September, AAPM convenes physicians, researchers, and policymakers in Washington, D.C. for scientific programming and direct policy engagement.
New White Paper · 2026 Edition
A Regulatory Framework for Peptide Therapeutics
Dr. Pradeep Albert, MD, and AAPM propose a tiered, risk-based framework that aligns regulatory burden with real patient risk — preserving the FDA's mission while restoring access to safe, lower-cost peptide therapies.
- A Three-Tier FrameworkRisk-adjusted oversight for endogenous, modified, and novel synthetic peptides.
- Scientific RationaleWhy peptides are pharmacologically distinct from small molecules and large biologics.
- Compound Status ChartCurrent regulatory status of Ta1, BPC-157, CJC-1295/Ipamorelin, GLP-1s, and more.
Why AAPM Matters
The credibility and leadership behind the Academy
Our founding advisory board includes former governors from both Republican and Democratic administrations, signaling that patient access to safe peptide medicine transcends party lines.
Board members include leading FDA regulatory attorneys, pharmacy law experts, and former state officials with deep experience in healthcare policy and compliance.
AAPM brings together physicians, researchers, pharmacists, and policymakers under one professional society to advocate for fair, science-driven oversight of peptide therapies. Our annual Washington D.C. conference each September convenes the field for scientific programming, peer exchange, and direct policy engagement.
The Future of Peptide Access
FDA PCAC Hearing • July 23-24, 2026
The FDA committee will review peptides nominated for the 503A compounding list. Follow the hearing and tell the FDA where you stand before the comment window closes.